APA (7th ed.) Citation

Hirota, Y., Kakei, Y., Imai, J., Katagiri, H., Ebihara, K., Wada, J., . . . Ogawa, W. (2024). A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01). Diabetes therapy, 15(2), 533-545. https://doi.org/10.1007/s13300-023-01526-x

Chicago Style (17th ed.) Citation

Hirota, Yushi, et al. "A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01)." Diabetes Therapy 15, no. 2 (2024): 533-545. https://doi.org/10.1007/s13300-023-01526-x.

MLA (9th ed.) Citation

Hirota, Yushi, et al. "A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01)." Diabetes Therapy, vol. 15, no. 2, 2024, pp. 533-545, https://doi.org/10.1007/s13300-023-01526-x.